{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:52:10Z","timestamp":1783075930854,"version":"3.54.6"},"reference-count":37,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T00:00:00Z","timestamp":1536624000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:p>Letermovir is a human cytomegalovirus (CMV) terminase inhibitor for the prophylaxis of CMV infection in allogeneic hematopoietic stem\u2010cell transplant (HSCT) recipients.<jats:italic>In vitro<\/jats:italic>, letermovir is a time\u2010dependent inhibitor and an inducer of cytochrome P450 (CYP)3A, and an inhibitor of CYP2C8 and organic anion transporting polypeptide (OATP)1B. A stepwise approach was taken to qualify the interaction model of an existing letermovir physiologically based pharmacokinetic model to predict letermovir interactions with CYP3A and OATP1B. The model was then used to prospectively predict the interaction between letermovir and CYP2C8 substrates such as repaglinide, a substrate of CYP2C8, CYP3A, and OATP1B. The results showed that letermovir modestly increased the exposure of CYP2C8 substrates. These results were used to inform the US prescribing information in the absence of clinical drug\u2013drug interaction studies. In addition, midazolam interactions with letermovir at therapeutic doses were also simulated to confirm that letermovir is a moderate CYP3A inhibitor.<\/jats:p>","DOI":"10.1002\/cpt.1120","type":"journal-article","created":{"date-parts":[[2018,6,14]],"date-time":"2018-06-14T11:25:28Z","timestamp":1528975528000},"page":"515-523","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["PBPK Modeling Strategy for Predicting Complex Drug Interactions of Letermovir as a Perpetrator in Support of Product Labeling"],"prefix":"10.1111","volume":"105","author":[{"given":"Ying\u2010Hong","family":"Wang","sequence":"first","affiliation":[{"name":"Merck Research Laboratories, Merck &amp; Co. West Point Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dapeng","family":"Chen","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, Merck &amp; Co. West Point Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgy","family":"Hartmann","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, Merck &amp; Co. West Point Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn R.","family":"Cho","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, Merck &amp; Co. West Point Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Menzel","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, Merck &amp; Co. West Point Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,9,11]]},"reference":[{"key":"e_1_2_9_1_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.05265-11"},{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0860-8"},{"key":"e_1_2_9_3_1","unstructured":"FDA.Letermovir Clinical Pharmacology and Biopharmaceutics Review. <https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/209939Orig1s000 209940Orig1s000ClinPharmR.pdf> (2017). Assessed 12 January 2018."},{"key":"e_1_2_9_4_1","unstructured":"McCrea A.A.et al.Letermovir moderately increases atorvastatin plasma exposure with coadministration. AAPS Annual Meeting and Exposition November 12\u201315 2017; San Diego CA;2017:M8081."},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1999.00030.x"},{"key":"e_1_2_9_6_1","unstructured":"FDA.Draft Guidance for Industry on Clinical Drug Interaction Studies \u2014 Study Design Data Analysis and Clinical Implications. <https:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/ucm292362.pdf> Accessed 24 October 2017."},{"key":"e_1_2_9_7_1","unstructured":"EMA.Guideline on the investigation of Drug Interactions (Final).2012. <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/07\/WC500129606.pdf>"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.0306-5251.2003.01862.x"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-003-1034-7"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2005.01.018"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.37"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1013"},{"key":"e_1_2_9_13_1","unstructured":"FDA.Lenvatinib clinical pharmacology biopharmaceutics review. <http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/206947s000lbl.pdf> (2014). Assessed 5 December 2016."},{"key":"e_1_2_9_14_1","unstructured":"FDA.Alectinib clinical pharmacology biopharmaceutics review. <http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/208434Orig1s000Lbl.pdf> (2015). Assessed December 5 2016."},{"key":"e_1_2_9_15_1","unstructured":"FDA.Canagliflozin Clinical Pharmacology Biopharmaceutics Review. <https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/204042Orig1s000ClinPharmR.pdf> (2013). Assessed 5 December 2016."},{"key":"e_1_2_9_16_1","unstructured":"EMA.Draft Guideline on the qualification and reporting of physiologically based pharmacokinetic modeling and simulation. <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2016\/07\/WC500211315.pdf> (2016). Assessed 25 January 2017."},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.30"},{"key":"e_1_2_9_18_1","unstructured":"PREVYMIS prescribing information. 2017. <http:\/\/www.prevymis.com>"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100220"},{"key":"e_1_2_9_20_1","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/S0090-9556(24)15086-6","article-title":"Lactonization is the critical first step in the disposition of the 3\u2010hydroxy\u20103\u2010methylglutaryl\u2010CoA reductase inhibitor atorvastatin","volume":"28","author":"Jacobsen W.","year":"2000","journal-title":"Drug Metab. Dispos."},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.33"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.79"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2015.06.019"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.02027.x"},{"key":"e_1_2_9_25_1","unstructured":"FDA.Teriflunomide Clinical Pharmacology Biopharmaceutics Review. <http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/202992Orig1s000ClinpharmR.pdf> (2012). Accessed 13 November 2016."},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-013-0097-y"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.24.53"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.116.070276"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425250802691074"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.110.032177"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2011.04.008"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.391"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.112.049460"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.114.059105"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1083-8791(03)00076-4"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-016-0378-6"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-016-2057-6"}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpt.1120","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.1120","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpt.1120","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.1120","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T03:42:45Z","timestamp":1751686965000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.1120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,11]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["10.1002\/cpt.1120"],"URL":"https:\/\/doi.org\/10.1002\/cpt.1120","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,11]]},"assertion":[{"value":"2018-03-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-09-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}